Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jai Radhakrishnan

Showing results (101-110 of 225) with videos related to

Pageof 23
Sort By:
European Journal of Haematology|February 24, 2025
Improved Outcomes of Myeloma Cast Nephropathy in Newly Diagnosed Multiple Myeloma With Modern Anti-Myeloma TherapiesMichael Sang Hughes, Metodi Balev, Jai Radhakrishnan, et al.
Journal of the American Society of Nephrology : JASN|July 25, 2000
Lithium nephrotoxicity: a progressive combined glomerular and tubulointerstitial nephropathyGlen S Markowitz, Jai Radhakrishnan, Neeraja Kambham, et al.
Kidney International|September 3, 2010
Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalitiesLeal C Herlitz, Sumit Mohan, Michael B Stokes, et al.
Transplantation|March 22, 2002
Angiotensin converting enzyme inhibition in chronic allograft nephropathyJulie Lin, Anthony M Valeri, Glen S Markowitz, et al.
Kidney International Reports|December 22, 2025
Defining Disease Modification in IgA Nephropathy: Toward a Paradigm Shift in ManagementJonathan Barratt, Laura H Mariani, Jai Radhakrishnan, et al.
Journal of the American Society of Hypertension : JASH|September 22, 2012
Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapyAndrew S Bomback, Yelena Rekhtman, Philip J Klemmer, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 26, 2020
How COVID-19 Has Changed the Management of Glomerular DiseasesAndrew S Bomback, Pietro A Canetta, Wooin Ahn, et al.
Kidney International|November 6, 2009
Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritisJai Radhakrishnan, Dimitrios-Anestis Moutzouris, Ellen M Ginzler, et al.
American Journal of Hematology|August 3, 2024
Timing and outcomes of second-line therapy in the era of daratumumab-based frontline therapy in AL amyloidosisAbdul-Hamid Bazarbachi, Divaya Bhutani, Jai Radhakrishnan, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 19, 2003
Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicityR Graham Barr, Stephen Seliger, Gerald B Appel, et al.
Pageof 23

Showing results (101-110 of 225) with videos related to

Sort By:
Pageof 23
European Journal of Haematology|February 24, 2025
Improved Outcomes of Myeloma Cast Nephropathy in Newly Diagnosed Multiple Myeloma With Modern Anti-Myeloma TherapiesMichael Sang Hughes, Metodi Balev, Jai Radhakrishnan, et al.
Journal of the American Society of Nephrology : JASN|July 25, 2000
Lithium nephrotoxicity: a progressive combined glomerular and tubulointerstitial nephropathyGlen S Markowitz, Jai Radhakrishnan, Neeraja Kambham, et al.
Kidney International|September 3, 2010
Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalitiesLeal C Herlitz, Sumit Mohan, Michael B Stokes, et al.
Transplantation|March 22, 2002
Angiotensin converting enzyme inhibition in chronic allograft nephropathyJulie Lin, Anthony M Valeri, Glen S Markowitz, et al.
Kidney International Reports|December 22, 2025
Defining Disease Modification in IgA Nephropathy: Toward a Paradigm Shift in ManagementJonathan Barratt, Laura H Mariani, Jai Radhakrishnan, et al.
Journal of the American Society of Hypertension : JASH|September 22, 2012
Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapyAndrew S Bomback, Yelena Rekhtman, Philip J Klemmer, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 26, 2020
How COVID-19 Has Changed the Management of Glomerular DiseasesAndrew S Bomback, Pietro A Canetta, Wooin Ahn, et al.
Kidney International|November 6, 2009
Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritisJai Radhakrishnan, Dimitrios-Anestis Moutzouris, Ellen M Ginzler, et al.
American Journal of Hematology|August 3, 2024
Timing and outcomes of second-line therapy in the era of daratumumab-based frontline therapy in AL amyloidosisAbdul-Hamid Bazarbachi, Divaya Bhutani, Jai Radhakrishnan, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 19, 2003
Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicityR Graham Barr, Stephen Seliger, Gerald B Appel, et al.
Pageof 23